Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(3):448–450. doi: 10.1038/bjc.1997.75

Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors.

G Paone 1, G De Angelis 1, L Portalone 1, S Greco 1, S Giosué 1, A Taglienti 1, A Bisetti 1, F Ameglio 1
PMCID: PMC2063371  PMID: 9020496

Abstract

By means of a mathematical score previously generated by discriminant analysis on 90 lung cancer patients, a new and larger group of 261 subjects [209 with non-small-cell lung cancer (NSCLC) and 52 with small-cell lung cancer (SCLC)] was analysed to confirm the ability of the method to distinguish between these two types of cancers. The score, which included the serum neuron-specific enolase (NSE) and CYFRA-21.1 levels, permitted correct classification of 93% of the patients. When the misclassifications were analysed in detail, the most frequent errors were associated with limited disease SCLC with low NSE levels and with advanced NSCLC with high NSE levels. This demonstrates the importance of the marker in correctly categorizing patients.

Full text

PDF
448

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ameglio F., Abbolito M. R., Giannarelli D., Citarda F., Grassi A., Gandolfo G. M., Casale V. Detection of Helicobacter pylori carriers by discriminant analysis of urea and pH levels in gastric juices. J Clin Pathol. 1991 Aug;44(8):697–698. doi: 10.1136/jcp.44.8.697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ameglio F., Giannarelli D., Cordiali-Fei P., Pietravalle M., Alemanno L., Paone G., Amicosante M., Saltini C., Bisetti A. Use of discriminant analysis to assess disease activity in pulmonary tuberculosis with a panel of specific and nonspecific serum markers. Am J Clin Pathol. 1994 Jun;101(6):719–725. doi: 10.1093/ajcp/101.6.719. [DOI] [PubMed] [Google Scholar]
  3. Burghuber O. C., Worofka B., Schernthaner G., Vetter N., Neumann M., Dudczak R., Kuzmits R. Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Cancer. 1990 Mar 15;65(6):1386–1390. doi: 10.1002/1097-0142(19900315)65:6<1386::aid-cncr2820650623>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  4. Carney D. N., Marangos P. J., Ihde D. C., Bunn P. A., Jr, Cohen M. H., Minna J. D., Gazdar A. F. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet. 1982 Mar 13;1(8272):583–585. doi: 10.1016/s0140-6736(82)91748-2. [DOI] [PubMed] [Google Scholar]
  5. Cooper E. H. Neuron-specific enolase. Int J Biol Markers. 1994 Oct-Dec;9(4):205–210. doi: 10.1177/172460089400900401. [DOI] [PubMed] [Google Scholar]
  6. Cooper E. H., Splinter T. A., Brown D. A., Muers M. F., Peake M. D., Pearson S. L. Evaluation of a radioimmunoassay for neuron specific enolase in small cell lung cancer. Br J Cancer. 1985 Sep;52(3):333–338. doi: 10.1038/bjc.1985.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Diez M., Torres A., Ortega L., Maestro M., Hernando F., Gomez A., Picardo A., Granell J., Balibrea J. L. Value of serum neuron-specific enolase in nonsmall cell lung cancer. Oncology. 1993 Mar-Apr;50(2):127–131. doi: 10.1159/000227163. [DOI] [PubMed] [Google Scholar]
  8. Ferrigno D., Buccheri G., Biggi A. Serum tumour markers in lung cancer: history, biology and clinical applications. Eur Respir J. 1994 Jan;7(1):186–197. doi: 10.1183/09031936.94.07010186. [DOI] [PubMed] [Google Scholar]
  9. Gail M. H., Muenz L., McIntire K. R., Radovich B., Braunstein G., Brown P. R., Deftos L., Dnistrian A., Dunsmore M., Elashoff R. Multiple markers for lung cancer diagnosis: validation of models for advanced lung cancer. J Natl Cancer Inst. 1986 May;76(5):805–816. [PubMed] [Google Scholar]
  10. Paone G., De Angelis G., Munno R., Pallotta G., Bigioni D., Saltini C., Bisetti A., Ameglio F. Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1. Eur Respir J. 1995 Jul;8(7):1136–1140. doi: 10.1183/09031936.95.08071136. [DOI] [PubMed] [Google Scholar]
  11. Wieskopf B., Demangeat C., Purohit A., Stenger R., Gries P., Kreisman H., Quoix E. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest. 1995 Jul;108(1):163–169. doi: 10.1378/chest.108.1.163. [DOI] [PubMed] [Google Scholar]
  12. van Zandwijk N., Jassem E., Bonfrer J. M., Mooi W. J., van Tinteren H. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol. 1992 Feb;19(1 Suppl 2):37–43. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES